Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Watched so hard i bought a bunch 😂
We also seek to create value through innovation and leveraging existing technologies into adjacent medical applications. We plan to expand our product line and clinical applications by developing enhancements and transformational innovations, including new clinical solutions for dental applications and for other adjacent medical applications.
In particular, we believe that our existing technologies can provide significant improvements over existing standards of care in fields including ophthalmology, otolaryngology, orthopedics, podiatry, pain management, aesthetics/dermatology, veterinary, and consumer products.
We plan to continue to explore potential collaborations to apply our proprietary laser technologies with expanded FDA-cleared indications to other medical applications in the future.
They make decent revenue $45 million
But not sure how much liability
Looks like they are addressing that now lol
Welcome to the wild world of debt heavy small caps.. I just took a position @.135, we’ll soon see how bright that was, lol..
Crazy shit
Debt converters..
Who the fuck is selling at this level?
Don’t make sense. I guess it trigger all the stops
44cents offering trading at 16cents?
Just wow. Massive dilution and all for a paltry $7m as a Hail Mary. That has to give pretty good insight into the direction of this company.
They've really screwed their investors over the last couple years, I'm sure they'll get enough idiots to buy to reach $7m but I have to say they wouldn't be able to raise any real money due to the lack of confidence in the management team and the product.
They are doing an offering
Pretty much the future scenario or a delist or Chap 11
Not all will survive
BIOL new 52 week low.... so far lol.. give it time, it will be sub-penny or an RS soon.
Must be time for another RS - may as well kill the shareholders again, no one is buying now.
Landmark Study Performed by the Independent McGuire Institute Confirms Positive 12 Month Clinical Outcomes for BIOLASE REPAIR® Perio Protocol
Validates BIOLASE REPAIR® Perio Protocol is a Superior Alternative as it pertains to patient reported outcomes.
LAKE FOREST, Calif., Nov. 8, 2023 /PRNewswire/ -- BIOLASE, Inc.(NASDAQ: BIOL), the global leader in dental lasers, today announced groundbreaking findings from a 12-month follow-up to a clinical trial performed at The McGuire Institute™. The findings will be published in the November 2023 issue of the Journal of Periodontology. The pioneering study was designed to meet the stringent American Association of Periodontology Best Evidence Consensus (BEC) standards, and is the first-of-its-kind study to compare BIOLASE's REPAIR® Perio protocol to the traditional minimally invasive surgical technique (MIST) treatment of moderate to severe generalized periodontitis.
Key highlights include:
Clinically Proven and Validated by Scientific ResearchThe study confirms that BIOLASE's Waterlase REPAIR® Perio protocol has similar and sustainable clinical outcomes as compared to traditional MIST in treating intrabony defects over the 12-month study thus reaffirming rigorous scientific research and the laser's clinical efficacy.
Enhanced Positive Patient ExperiencePatients who underwent BIOLASE's Waterlase REPAIR® Perio laser treatment reported significantly better patient-reported outcomes (PROs) at six months. These findings show that patients experienced less pain, reduced bleeding, and minimal discomfort, indicating a patient-friendly approach to periodontal care.
Safety and Minimal InvasivenessThe study found no adverse events associated with BIOLASE's Waterlase REPAIR® Perio laser procedure, highlighting its safety. Furthermore, it emphasizes that this laser treatment is minimally invasive, ensuring a highly effective and more comfortable experience for patients.
Faster RecoveryPatients in the BIOLASE Waterlase group reported a quicker reduction in swelling and discomfort, suggesting a faster and more comfortable recovery compared to traditional treatment.
"This exciting study provides further strong evidence that our Waterlase laser and REPAIR® Perio protocol is a safe and effective alternative to surgical treatment for intrabony periodontal defects with lasting results," said Dr. Russell Morrow, the Chief Dental Officer at BIOLASE. "The results ensure patients will not have to compromise on effectiveness, or comfort when choosing a less invasive approach."
BIOLASE's Waterlase laser is a minimally invasive laser that can be used to treat a variety of dental conditions, including intrabony periodontal defects. Intrabony periodontal defects are pockets that form between the tooth and bone and can lead to tooth loss. The Waterlase laser works by vaporizing the diseased tissue and stimulating the body to produce new bone and gum tissue.
"The study provides a firm rationale for an alternative surgical approach in the treatment of intrabony periodontal defects and forges the path for future comparisons using regenerative therapies in conjunction with the REPAIR® Perio technique," said Rick H. Heard, DDS, MS and Executive Director of Clinical Research and Operations of the McGuire Institute, a network of master clinicians trained and qualified to conduct high level clinical research in a practice based setting and located strategically throughout the United States. "It also supports superiority over a minimally invasive surgical technique with respect to patient reported outcomes."
Additionally, the McGuire study has earned a well-deserved nomination for the 2024 DrBicuspid Dental Excellence Awards, affectionately known as the "Cuspies," a platform to honor the best in dental innovation and excellence. Among the esteemed categories, the "Dental Study of the Year" spotlights research that promises to reshape the future of dental practice.
Winning this prestigious award at the Cuspies would not only be an accolade, but a testament to how the McGuire study could potentially redefine and elevate the standard of care for periodontal patients globally. It is an opportunity to celebrate a study with the power to reshape the landscape of periodontal treatment, setting new benchmarks for excellence in the dental field.
About BIOLASE
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. As of December 31, 2022, BIOLASE's proprietary laser products incorporate approximately 259 patented and 24 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2022, BIOLASE has sold over 45,500 laser systems in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements, regarding BIOLASE's expected revenue and revenue growth and beliefs regarding its financial resources. Forward-looking statements can be identified through the use of words such as "may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the outbreak and actions taken in connection therewith, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's most recent annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.
For further information, please contact:
Well now we know why it's been steadily dropping even with the YOY improvements to revenue.
Dilute, Dilute, Dilute.
Sigh. Stock market scam.
BIOL going up!! don't miss it!!
low float!!
BIOL Great time to get a position!!
don't miss it!!
Ouch down 50% premarket.. 1,69 bid
New lows
BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
Yeah, I suspect they're doing much worse than outsiders realize - they've actually created revenue and YOY growth and yet the PPS keeps going lower and lower even after the massive RS. I suspect it won't be long before we learn of some kind of structural issue within the company that hasn't been discussed so far.
Lets see how low they will push it. It already took quite a harcut from over $8.
It just keeps getting worse. Sigh.
1:100 - unbelievable!!
The company management team should all be arrested! What person in their right mind has ANY confidence in ANYTHING these people touch for the rest of their careers??!
That is literally scandalous! 1:100?!?!?!?
This is theft in plain sight!!!
After 30. years anniversary on the NASDAQ I don’t believe they want it to delist. The company doing progress, it makes more sense to stay on Nasdaq and be accessible to wide range of investors. To pull a rabbit is possible, but I don’t believe it at the moment. They are preparing for the RS. IMHO. GLTA
https://finance.yahoo.com/news/biolase-announces-distribution-series-preferred-213000897.html
Does anyone believe they can pull a rabbit out of their hat and get back to a dollar before 7-10? Would a RS be their direction or let it de-list?
Hard to believe how hard-hit the market has been this past couple years isn't it? And this company has an actual product!!
What are the best sides to look at for insider buying? Thanks
Insider bought 7,000,000 shares in last 5 months and institutions have added also
Followers
|
55
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1237
|
Created
|
11/06/07
|
Type
|
Free
|
Moderators |
www.biolase.com
http://finance.yahoo.com/q/ks?s=BIOL+Key+Statistics
BIOLASE Technology, Inc., a medical technology company, develops, manufactures, and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and medicine. Its principal products provide dental laser systems that allow general dentists, periodontists, endodontists, oral surgeons, and other specialists to perform a range of dental procedures, including cosmetic and complex surgical applications. The company offers two categories of laser system products comprising Waterlase systems and Diode systems. The Waterlase systems use a combination of water and laser to perform dental procedures primarily cutting soft and hard tissue plus bone. Its Waterlase systems include the Waterlase iPlus, the Waterlase MD Turbo, and the Waterlase C100 All-Tissue Dental Laser System. The Diode systems consists of the ezlasetm and iLase, semiconductor diode lasers to perform soft tissue, hygiene, and cosmetic procedures, including teeth whitening and pain relief. The company also provides medical systems, such as the Diolase 10 diode laser for dental and medical pain relief applications, as well as disposable products and related accessories for its laser systems. In addition, it offers dental imaging equipment. BIOLASE Technology, Inc. sells its products through direct sales force and a network of independent distributors in the United States and internationally. The company was formerly known as Societe Endo Technic, SA and changed its name to BIOLASE Technology, Inc. in 1994. BIOLASE Technology, Inc. was founded in 1984 and is headquartered in Irvine, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |